HARVARD BIOSCIENCE, INC. Proceeds from Lines of Credit
HARVARD BIOSCIENCE, INC. (HBIO) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-03-13
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $0.00.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for fiscal 2024 was $8.80M, a 95.56% increase from fiscal 2023.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for fiscal 2023 was $4.50M, a 42.31% decline from fiscal 2022.
- HARVARD BIOSCIENCE, INC. proceeds from lines of credit for fiscal 2022 was $7.80M, a 83.53% increase from fiscal 2021.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-13 | $0.00 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-13 | $3.25M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $3.25M derived: sum of 3 quarters · filed 2026-03-13 | $6.30M derived: sum of 4 quarters · filed 2026-03-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $3.25M derived: sum of 2 quarters · filed 2026-03-13 | $6.30M derived: sum of 3 quarters · filed 2026-03-13 | $8.80M 10-K · filed 2026-03-13 |
| 2024-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.30M derived: sum of 2 quarters · filed 2025-11-06 | $8.80M 10-Q · filed 2025-11-06 | $9.80M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.55M 10-Q · filed 2025-08-11 | $6.55M derived: sum of 3 quarters · filed 2025-08-11 | $7.55M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.50M 10-Q · filed 2025-05-12 | $3.50M derived: sum of 2 quarters · filed 2025-05-12 | $4.50M derived: sum of 3 quarters · filed 2025-05-12 | $5.50M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $2.00M derived: sum of 2 quarters · filed 2025-03-14 | $3.00M derived: sum of 3 quarters · filed 2025-03-14 | $4.50M 10-K · filed 2025-03-14 |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.00M derived: sum of 2 quarters · filed 2024-11-08 | $3.50M 10-Q · filed 2024-11-08 | $3.50M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.50M 10-Q · filed 2024-08-08 | $2.50M derived: sum of 3 quarters · filed 2024-08-08 | $5.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-07 | $1.50M derived: sum of 2 quarters · filed 2024-05-07 | $4.00M derived: sum of 3 quarters · filed 2024-05-07 | $7.80M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $2.50M derived: sum of 2 quarters · filed 2024-03-07 | $6.30M derived: sum of 3 quarters · filed 2024-03-07 | $7.80M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $6.30M derived: sum of 2 quarters · filed 2023-11-07 | $7.80M 10-Q · filed 2023-11-07 | $9.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.30M 10-Q · filed 2023-08-08 | $7.05M derived: sum of 3 quarters · filed 2023-08-08 | $9.55M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.50M 10-Q · filed 2023-04-26 | $3.25M derived: sum of 2 quarters · filed 2023-04-26 | $5.75M derived: sum of 3 quarters · filed 2023-04-26 | $5.75M derived: sum of 4 quarters · filed 2023-04-26 |
| 2021-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.25M derived: sum of 2 quarters · filed 2023-03-09 | $4.25M derived: sum of 3 quarters · filed 2023-03-09 | $4.25M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.50M derived: sum of 2 quarters · filed 2022-11-09 | $2.50M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |